Zai Lab CFO Chen Yajing sells 260 ADS worth $7,020
PUBT·- Zai Lab CFO Chen Yajing sold 260 American Depositary Shares on Aug. 19, 2026, at USD 27 per share for a total of USD 7,020. - Following this transaction, executed under a Rule 10b5-1 plan adopted on Dec. 9, 2025, direct holdings totaled 35,635 ADS. - The transaction details were disclosed in a filing submitted to the U.S. Securities and Exchange Commission on August 21, 2026.Zai Lab (ZLAB) Posts Positive Phase 3 Results In Autoimmune Myositis
Simplywall·- Zai Lab and argenx announced positive Phase 3 ALKIVIA trial results for VYVGART Hytrulo in treating autoimmune myositis. - The successful trial represents a significant milestone for immune-mediated necrotizing myopathy, an underserved rare muscle disease with no previously approved therapies. - This development reinforces Zai Lab's immunology portfolio expansion while highlighting its reliance on externally sourced partnerships and licensed assets.Top 10 HK Stock Gainers (8.19)
Top Gainers&Losers·Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock
Market Beat·- Zai Lab CFO Yajing Chen sold 619 shares of stock at an average price of $25.00 on August 11th, reducing her position by 1.73% to 35,072 shares. - The transaction was disclosed in an SEC filing, following a previous sale of 2,264 shares on June 26th at an average price of $17.46. - Zai Lab holds a market cap of $2.96 billion and maintains a Moderate Buy consensus rating with an average target price of $40.20 among analysts.Zai Lab CFO Chen Yajing sells 619 ADS worth $15,475
PUBT·- Zai Lab CFO Chen Yajing sold 619 American Depositary Shares on Aug. 11, 2026, at a price of USD 25 per share. - The transaction total amounted to USD 15,475, reducing the CFO's holdings to 35,072 American Depositary Shares. - This regulatory filing information was published via the SEC EDGAR system on August 13, 2026.Zai Lab audit committee to review and approve interim results publication
PUBT·- Zai Lab's audit committee meeting is scheduled for Aug. 25, 2026, U.S. Eastern Time, or Aug. 26, 2026, Hong Kong Time. - The session will review and approve the company's unaudited condensed consolidated interim results for the six months ended June 30, 2026. - The original regulatory disclosure was published via the Hong Kong Stock Exchange IIS on August 13, 2026.MSCI China Index Adds Z.AI and KINGBOARD HLDG
AASTOCKS News·- MSCI announced the results of its quarterly review, adding 33 stocks and removing 32 stocks from the MSCI China Index. - Key additions to the index include companies such as Z.AI and KINGBOARD HLDG, while notable removals feature GCL TECH and KINGDEE INT'L. - The index adjustments are scheduled to take effect after the market close on August 31.Zai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?
Market Beat·- Zai Lab shares recently gapped down to open at $25.00 following a previous close of $26.00. - Several equities analysts have recently adjusted their ratings and price targets, resulting in a consensus rating of Moderate Buy and an average target price of $40.20. - Financial metrics indicate a market capitalization of $2.90 billion, along with recent insider stock sales and institutional holding updates.CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)
Tip Ranks·- CICC maintained a Buy rating on Zai Lab Ltd with a price target of HK$ 20.20 in a recent report. - The broader analyst consensus on the stock stands at a Strong Buy alongside an average price target of € 3.03.Citi Raises Zai Lab Limited TP to USD45, Expects China Business to Stabilize in 2H26
AASTOCKS News·- Citi reported that Zai Lab Limited achieved 2Q product revenue of approximately USD 106 million, up about 11% QoQ and matching market expectations. - The broker raised Zai Lab Limited's US stock target price from USD 44 to USD 45 while maintaining a Buy/High Risk rating. - This adjustment factors in Tivdak's approval from the National Medical Products Administration alongside anticipated pipeline developments and upcoming catalysts.Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings
Market Beat·- Zai Lab shares rose 14.5% to $21.0250 following a stronger-than-expected earnings report for the quarter. - The biopharmaceutical company posted earnings per share of ($0.50) and revenue of $106.31 million, both beating analyst consensus estimates. - Market activity showed a trading volume of 84,247 shares alongside recent insider stock sales by company executives.U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) | ZLAB Stock News
StockTitan·- The U.S. FDA has granted Orphan Drug Designation to Zai Lab’s DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan for treating neuroendocrine carcinomas. - This regulatory designation aims to accelerate clinical development by providing development incentives, tax credits, and potential market exclusivity for the treatment of aggressive malignancies. - Zai Lab plans to advance registration-enabling studies across various small cell lung cancer and extrapulmonary neuroendocrine carcinoma indications by the end of 2026.UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)
Tip Ranks·- UBS maintained a Buy rating on Zai Lab Ltd with a price target of HK$ 27.00 in a report released on July 27. - The company's shares closed at HK$ 14.87 on the preceding Friday. - The broader market consensus for Zai Lab Ltd reflects a Moderate Buy rating.Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 | ZLAB Stock News
StockTitan·- Zai Lab Limited will report its second quarter 2026 financial results on August 6, 2026, before U.S. equity markets open. - The announcement will be followed by a conference call and webcast at 8:00 a.m. ET, with registration required for participants. - Zai Lab, a biopharmaceutical company based in China and the U.S., focuses on innovative products in oncology, immunology, neuroscience, and infectious disease.